Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protagonist Therapeutics Inc PTGX

Healthcare Biotechnology
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its... see more

Recent & Breaking News (NDAQ:PTGX)

Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

PR Newswire May 7, 2020

Protagonist Therapeutics to Announce First Quarter 2020 Financial Results and Provide Corporate and R&D Update

PR Newswire May 4, 2020

Protagonist Therapeutics Reports Granting of Inducement Award

PR Newswire April 15, 2020

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

PR Newswire March 10, 2020

Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results

PR Newswire March 2, 2020

Protagonist Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference in New York

PR Newswire February 19, 2020

Protagonist Therapeutics to Present Preclinical Results on PN-943 at the 15th Congress of European Crohn's and Colitis Organization (ECCO)

PR Newswire February 7, 2020

Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration

PR Newswire January 7, 2020

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis

PR Newswire January 6, 2020

Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia

PR Newswire December 3, 2019

Protagonist Therapeutics to Present at Two Upcoming Healthcare Investor Conferences

PR Newswire November 13, 2019

Protagonist Therapeutics Reports Third Quarter 2019 Financial Results

PR Newswire November 6, 2019

Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease

PR Newswire November 6, 2019

Protagonist Therapeutics Secures Debt Facility for up to $50 Million

PR Newswire October 31, 2019

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera

PR Newswire October 30, 2019

Protagonist Therapeutics Announces Acceptance of Abstracts at the UEG Week 2019 Meeting and the ACG 2019 Annual Scientific Meeting

PR Newswire October 1, 2019

Protagonist Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 2

PR Newswire September 25, 2019

Protagonist Therapeutics Reports Granting of Inducement Awards

PR Newswire September 4, 2019

Protagonist Therapeutics to Present at the H.C. Wainwright & Co. 2019 Annual Healthcare Conference

PR Newswire September 3, 2019

Protagonist Therapeutics Reports Second Quarter 2019 Financial Results

PR Newswire August 7, 2019